Geneva – 26 September 2014. UNITAID releases today its 2014 Tuberculosis Diagnostics Technology and Market Landscape, detailing the promising pipeline of products and technologies to diagnose tuberculosis (TB). The report highlights current and emerging technologies from over 80 manufacturers and developers, including products which are smaller, simpler and easier to use in decentralized settings than the current tools used by the majority of high-burden TB countries.
24th September 2014 - Chair of the UNITAID Executive Board and United Nations Secretary General's Special Advisor on Innovative Financing for Development, Philippe Douste-Blazy, gave an opening address at the Leading Group on Innovative Financing for Development in New York. The event's theme was "Innovative financing: a solution to diversify the financial toolbox for sustainable development and the climate".
23rd September 2014 - UNITAID’s Chair of the Executive Board, Philippe Douste-Blazy joined other high level guests at the ‘A Vision for 2030’ event in New York, held during the week of the 69th UN General Assembly in the lead up to the 3rd Annual Global Citizen Festival to honour people fighting extreme poverty and working for an AIDS-free generation. Dr Douste-Blazy spoke on the clear link between AIDS and poverty and the need for concerted action.
19th September – on the eve of the 69th United National General Assembly, UNITAID is celebrating its 8th anniversary. It was in 2006 at the opening of the 61st UNGA that UNITAID was officially launched by Brazil, France, Chile, Norway and the United Kingdom.
Geneva - 15 July 2014 - UNITAID has released its Fourth Edition of the HIV Diagnostic Technology Landscape, the global health community’s key reference on the pipeline of promising new technologies to detect and monitor HIV treatment in resource-constrained settings. First released in June 2011 and updated annually, this report is used by health care providers, donors and developers to help guide the future response to the disease.
Geneva - 15 July 2014 - UNITAID has released its 2014 Malaria Diagnostics Technology and Market Landscape, which includes an overview of the current diagnostics technology and market landscape, a high-level perspective on barriers to access of key products and potential opportunities for market-based interventions to address these barriers.
You can access the landscape report here. Part of UNITAID’s wider landscaping efforts for HIV/AIDS, malaria and tuberculosis, this report is part of a regular series of updates on the malaria diagnostics market.
UNITAID has released its first guidance documment on procurement by grantees.
Procurement of Health Products - An Operational Guideline for UNITAID Grantees is intended to provide guidance to grantees on the development and transparent implementation of strategies and plans for accessing health products with funding provided by UNITAID. This important guideline has been developed in collaboration with Management Sciences for Health (MSH).
- Download the guideline [PDF, 3.3 MB]
Note: French version coming soon.
In recent years, the number of bilateral and regional trade negotiations has been increasing. Many of these negotiations involve both developed and developing countries, and the ensuing free trade agreements often contain extensive provisions on the protection of intellectual property rights. These provisions usually impose a higher level of protection for intellectual property rights than is required under the Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS Agreement. These so-called “TRIPS-plus” provisions delay generic market entry and competition. As such, they run counter to UNITAID’s efforts to increase the affordability of, and access to, medicines and other medical products.
Geneva – 9 April 2014 – The World Health Organization’s (WHO) new Guidelines on Treatment of Hepatitis C recommending the use of the newly available and vastly improved medicines for hepatitis C are very much welcome. Increasing competition for production of the new medicines is needed to significantly reduce the currently prohibitively high prices to enable access for the up to 30 million people which WHO estimates are in need of treatment. However, screening and diagnosis of vulnerable populations to identify patients and build market intelligence will be vital to encourage new manufacturers to enter the market. For now, screening and diagnosis are too complex and expensive for large-scale use in middle-income countries where over 75% of the disease burden lies. These were some of the conclusions from UNITAID’s HIV Market Forum, a gathering of global HIV experts, held in Geneva 7-8 April.
UNITAID has released its first HIV/AIDS Medicines Technology and Market Landscape Technical Report.
This comprehensive study reviews access to antiretroviral therapy (ART) in low and middle- income countries based on extensive medicine technology and market analyses.
This Report highlights critical market shortcomings, underlying reasons for market failures and potential approaches to correcting them.
- Study calls for new funders to join UNITAID for WHO Prequalification
- UNITAID launches its first intelligence report on the malaria vector control commodities, technology and market landscape
- UNITAID publishes first scoping report on hepatitis C
- President Hollande calls for innovative financing as a solution for global insecurity
- 2013 Tuberculosis Medicines Technology and Market Landscape